Spire Healthcare Group (LON:SPI) Price Target Raised to GBX 300

Spire Healthcare Group (LON:SPI) had its target price raised by equities researchers at Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a report issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 20.97% from the company’s current price.

Separately, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a GBX 295 ($3.67) price target on shares of Spire Healthcare Group in a research note on Monday, February 26th.

Spire Healthcare Group Stock Up 4.0 %

Shares of Spire Healthcare Group stock opened at GBX 248 ($3.09) on Wednesday. The company has a debt-to-equity ratio of 170.37, a quick ratio of 0.74 and a current ratio of 0.69. Spire Healthcare Group has a 52-week low of GBX 204 ($2.54) and a 52-week high of GBX 321.71 ($4.00). The stock has a market capitalization of £1.00 billion, a price-to-earnings ratio of 3,542.86, a P/E/G ratio of 1.06 and a beta of 0.99. The company’s 50 day moving average price is GBX 237.57 and its 200-day moving average price is GBX 228.97.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.